by Maria Zannes | Oct 14, 2021 | Press Releases
Reveles leads CyPath® Lung, a non-invasive and highly accurate test for lung cancer, as it enters the market OCTOBER 14, 2021 (SAN ANTONIO, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations....
by Maria Zannes | Sep 29, 2021 | Events
Vice President of Research David Elzi, PhD, will present groundbreaking research leading to bioAffinity’s discovery of how silencing two cell receptors results in cancer cell toxicity, while normal cells are unaffected. His presentation at the American Society of...
by Maria Zannes | Sep 23, 2021 | Press Releases
Australian Patent Office Issues Notice of Acceptance for Patent Related to Porphyrin Compounds and Compositions to Treat Cancer SEPTEMBER 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office...
by Maria Zannes | Sep 16, 2021 | News
Alamo City company has reached critical milestone that could lead to more commercial opportunities SEPTEMBER 16, 2021 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San-Antonio Business Journal More than seven years after its...
by Maria Zannes | Sep 14, 2021 | Press Releases
CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer...
